Halozyme Therapeutics (HALO) announced that Takeda (TAK) received European Commission, or EC, approval for HYQVIA, or Immune Globulin Infusion 10%, co-formulated with Halozyme’s ENHANZE drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy, or CIDP, after stabilization with intravenous immunoglobulin therapy, or IVIG. HYQVIA also recently received FDA approval as maintenance therapy for adults with CIDP. HYQVIA is the only FDA and now EC-approved combination of immunoglobulin, or IG, and hyaluronidase for CIDP and is administered by facilitated subcutaneous infusion. For patients with CIDP, HYQVIA can be infused up to once monthly. HYQVIA can be administered by a healthcare professional or self-administered in the patient’s home after appropriate training.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HALO:
- Halozyme announces approval for Vydura in Japan
- Halozyme price target lowered to $48 from $61 at H.C. Wainwright
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
- Halozyme announces Roche receives EC marketing authorization of Tecentriq SC
- Halozyme to Host Investor Business Forum and Long-Term Outlook Call
